Monkeypox Vaccine and Treatment Market Size, Share, By Product Type (Vaccine (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others), and Vaccinia Immune Globulin), By Gender Type (Male, Female, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others (Government agencies)), and By Region - Trends, Analysis and Forecast till 2034

Monkeypox vaccine and treatment market size was valued at USD 85.4 Billion in 2024 and is expected to reach USD 215.7 Billion by 2034, growing at a CAGR of 10.7%

The Monkeypox vaccine and treatment market has been in the spotlight since the 2022 outbreak worldwide, which saw demand for vaccines overload against the spread of this virus. Before the outbreak, the market was small; it was mostly targeted at high-risk populations, such as laboratory workers and health professionals. Then again, what has happened in the current resurgence is a crystal indicator of preparedness for emerging infectious diseases and rapid expansion of the vaccine market. It means that the basis for the monkeypox vaccine market is the protection of vulnerable populations from the virus. The vaccine was developed in the 1970s and proved to be quite efficacious in preventing serious illness and death. However, it is not 100% efficient, and some people may still have mild symptoms. Government policies, public health initiatives, and resource availability for developing and distributing vaccines are thus the market determinants. Several key players within the Monkeypox vaccines market include pharmaceutical companies, government agencies, and research institutions. The primary activities include developing, manufacturing, distributing, and promoting the vaccine in the market. There is a high level of competition in the particular market because several companies compete for the same market share. The factors based on this success in the market are vital constants, such as the efficacy, safety, and price of the vaccine.

Following the outbreak, the surge in demand for the monkeypox vaccine has increased pressure on global supplies. Many countries faced shortages; some had to concentrate vaccination in high-risk groups. Now, the world needs more production capacity for vaccines and a fair distribution process. The future monkeypox vaccine market is, however, very uncertain. Though the current outbreak imparts the message of being prepared for emerging infectious diseases, the long-term requirements for these vaccines remain to be seen. Factors such as efficacy in public health measures, the development of other new vaccines, and the emergence of new virus variants will all play a part in the market's trajectory. Finally, the monkeypox vaccine market is fast-growing and has recorded colossally rapid growth over the past years. The global outbreak 2022 has made almost everybody realize the role of vaccination in preventing infectious diseases. However, long-term demand remains an open question, as the market depends on government policy, public health initiative strategies, and resource availability.

             For More Report Details, Download Free Sample PDF

Key Drivers of Target Market:

Government Operations and Funding

• Due to the increasing cases witnessed worldwide, governments have already provided finances for developing, researching, and stockpiling vaccines. The U.S. government has proactively allocated resources towards creating and stockpiling smallpox vaccines seen as applicable against monkeypox. This has also included contracts between the government and pharmaceutical companies for investment in manufacturing capacity. Similar efforts were mirrored in Europe, where the various governments jointly worked through the EMA to facilitate the approval and distribution of the vaccines.

Advancements in Vaccine Technology

• The technological advancements in vaccines, primarily using viral vectors and next-generation platforms like the mRNA vaccines, are driving the market. Traditional smallpox vaccines, like the MVA vaccine, have been engineered for cross-protection against monkeypox. These advances have produced more effective vaccines with reduced side effects, making healthcare professionals and the public more confident in vaccination. The rapid development and deployment of mRNA vaccines in the context of the COVID-19 pandemic provided a blueprint that is now being applied to the case of monkeypox.

Restrains:

High Cost of Research and Production

• High cost is involved in vaccine research and production, particularly those developed with advanced technologies. These costs are then transferred to the healthcare systems and, in most cases, the consumers, thereby reducing the accessibility of vaccines, mainly in low- and middle-income countries. Again, distribution logistics add to the overall cost because of requirements such as maintaining a cold chain, among other things. This creates access disparities resulting from the developed and developing regions.

Opportunities:

Investing In Next-Generation Vaccine Platforms

• The successful development of mRNA vaccines against COVID-19 proved the potential of next-generation platforms to address other infectious diseases, such as monkeypox. Investing in these technologies will lead to the development of superior, scalable vaccines. Companies investigate mRNA, viral vectors, and other new-generation platforms by harnessing development to produce vaccines that offer more excellent coverage and require fewer doses. That is the type of innovation capable of unlocking new market segments and driving up demand for vaccine high-tech solutions.

The market is segmented based on Product Type, Gender Type, Route of Administration, Distribution Channel, and Region.

Product Type Insights:

• Vaccine: Vaccines are biological entities used to stimulate a person's immune system, which results in the development of antibodies against a given disease. They introduce a weakened or inactivated form of a pathogen, or parts of it, into the body, which enables the immune system to recognize and fight off the pathogen when it meets one in the future. 
• JYNNEOS/Imvanex: JYNNEOS, known as Imvanex in Europe, is a non-replicating smallpox and monkeypox vaccine manufactured and developed by Bavarian Nordic. The attenuated virus vaccine is based on the modified vaccinia Ankara-Bavarian Nordic MVA-BN strain that is incapable of replication in human cells. It has a good safety profile and is licensed to prevent smallpox and monkeypox, particularly in high-risk populations. It is one of the vaccines used to respond to the recent monkeypox outbreaks.
• Smallpox Vaccine: Traditional smallpox vaccines, such as ACAM2000, have been used against monkeypox due to the proximity between the smallpox and monkeypox viruses. However, these classic vaccines against smallpox are usually live and replicating and so have higher risks for side effects, particularly in immunocompromised people. However, they form a significant arm in the stockpile of vaccines worldwide in emergency responses.
• Others: This would involve any such developing or repurposed vaccine used to prevent monkeypox. It may further constitute next?generation vaccines or even regionally specific solutions that could fix epidemiologically unique problems.
• Drugs: Any substance used as a medication, usually for the treatment, prophylaxis, or diagnosis of a disease or condition. Drugs can be natural or synthetic and often have been classified by their chemical structure or their therapeutic use. 
• Tecovirimat: Tecovirimat, also known as TPOXX, is an antiviral medication released for the treatment of smallpox but, in laboratory studies, has shown efficacy against monkeypox. The drug works by preventing the spread of the orthopox virus throughout the body. Because of its potential to reduce the duration and severity of monkeypox symptoms, it has been used off-label in many places during outbreaks.
• Brincidofovir: is another antiviral, developed primarily against smallpox but considered for treating monkeypox infection. It acts to limit viral DNA synthesis through replication inhibition. It is much less used than Tecovirimat, but still remains a treatment option, specifically for severe cases.
• Cidofovir: Cidofovir is an antiviral drug primarily designed for cytomegalovirus infections but recently repurposed for orthopoxvirus infections, including monkeypox. Its prescription is normally reserved for serious or complicated cases, but cidofovir constitutes part of the armamentarium against monkeypox.
• Others: may include any investigational antivirals or investigational supportive therapeutics being used or tested for the management of monkeypox infections. These may be different drug formulations or drug combinations that would improve the treatment outcomes.
• Vaccinia Immune Globulin (VIG): VIG is a purified human immunoglobulin that includes antibodies to the vaccinia virus, which is closely related to both smallpox and monkeypox. It is indicated for treating complications from vaccinia-based smallpox vaccines and has been used even in severe cases of monkeypox where traditional treatment is not effective. It represents an important tool in managing vaccine-associated adverse events and in severe manifestations of the diseases.

Gender Type insights:

• Male: In the light of monkeypox, men are an imperative demographic, especially in the areas where transmission most frequently occurs among the male who has sex with the male population. Vaccination strategies and therapeutic interventions can be tailored for certain risk factors and health behaviors clustering, most importantly, in a time of outbreak.
• Female: Though females have not been the target of most recent outbreaks, they are another imperative segment of the monkeypox vaccine market. Prevention, vaccination, and treatments against the virus are necessary measures to protect women, health workers, caregivers, or travelers who might have been exposed, directly or indirectly, to the infected persons.
• Others: This constitutes all other gender identities, which may be vulnerable to monkeypox infection, be it non-binary, transgender, or another such identity. Inclusive healthcare enables all gender identities to open up strategies for vaccination and treatment, given the diversity in health needs and vulnerabilities. Route of administration:

Route of Administration insights:

• Oral: This is simple and non-invasive in the course of treating monkeypox. It is easy to administer oral antiviral drugs in outpatient settings or places with little health infrastructure—pharmaceutical agents like Tecovirimat. This would make a big difference in the distribution, which would be less challenging, making compliance easier in places with high transmission rates.
• Injectable: this forms of vaccines and drugs are another critical factor in the prevention and treatment of monkeypox. Most vaccines, like JYNNEOS/Imvanex, are injectable to ensure a quick, effective immune response by the host. Other injectable antivirals and immunoglobulins are given to people in serious cases or in clinical settings where immediate intervention is required. This route is preferred more in hospital and clinical settings.

Distribution Channel insights:

• Hospital Pharmacies: The delivery of the monkeypox vaccines and antiviral treatments will take place with the help of pharmacies, especially in outbreak areas. A hospital setting is essential in the sense that all vaccines and medications will be delivered and under the supervision of a medic to handle any aforementioned adverse effects or complications that might come up. Hospital pharmacies are also crucial in the treatment of severe cases that cause the need for hospitalization.
• Retail Pharmacies Retail pharmacies improve monkeypox vaccine and treatment availability to the public in general. More specifically, they stock vaccines and antivirals and thus greatly offer accessibility to preventive procedures in urban and suburban settings. They play a very convenient role in helping people get vaccinated or treated without going to a hospital.
• Online Pharmacies: E-pharmacies have emerged as a key mode of distribution, especially in areas where e-commerce is prevalent. They allow many people to procure antiviral pharmaceuticals and vaccines in their homes' safety and comfort, ensuring remote access. This is particularly useful when some movements are limited or under lockdown.
• Others: Public health agencies and military medical forces are pivotal conduits during a state of public health emergency. Their core mission is to establish a fair and equitable dispersion of vaccines and treatments to all members of the public, especially those within underrepresented or vulnerable communities. These agencies will also conduct and coordinate mass vaccination efforts and execute the distribution of medical supplies in cases of outbreaks. Therefore, the mass agencies will form an integral part of the distribution chain.

Regional insights:

• North America: Strong healthcare infrastructure, high awareness, and proactive government measures in managing monkeypox outbreaks drive the North American market. In particular, outbreaks of this virus have fueled high demand for vaccination and subsequent treatment in the United States.
• Europe: this is the other major region, with established healthcare systems and response mechanisms that can coordinate very well. The European Union has made it easy to distribute vaccines such as Imvanex within its member states, assuring a unified way to combat monkeypox.
• Asia-Pacific: this is itself a very varied area in terms of the level of access to healthcare and infrastructure. While countries such as Australia will have pushed forward with strong vaccination campaigns, the rest of the nations may still be strategizing their responses. The increased investments in health and the high population density make this region a critical market for vaccines and treatments.
• Latin America: Sensitization and measures on monkeypox have been well taken, especially in countries such as Brazil. However, the perception of a response at regional levels might be challenged by many issues, including access to and funding of healthcare. Vaccination and treatment campaigns are significant in containing outbreaks within this region.
• Middle East & Africa: This region faces many unique challenges, including limited healthcare infrastructure and resources. However, it is already negotiating arrangements for vaccine and treatment access, especially for regions with a historical link to poxvirus outbreaks. An international aid facility and government measures are helping.

Monkeypox Vaccine and Treatment Market Report Scope:

Attribute	Details
Market Size 2024	USD 85.4 Billion
Projected Market Size 2034	USD 215.7 Billion
CAGR Growth Rate	10.7%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	Product Type- Type (Vaccine (JYNNEOS/ Imvanex, Smallpox Vaccine, Others), Drugs (Tecovirimat, Brincidofovir, Cidofovir, Others), and Vaccinia Immune Globulin) Gender Type- Male, Female, Others Route of Administration- Oral, Injectable Distribution Channel- Hospital Pharmaices, Retail Paharmacies, Online Pharmacies and Others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on Product Type, Gender Type, Route of Administration, Distribution Channel, and Region.

Segmentation:

By Product Type:

• Vaccine
  • JYNNEOS/ Imvanex
  • Smallpox Vaccine
  • Others
• Drugs
  • Tecovirimat
  • Brincidofovir
  • Cidofovir
  • Others
• Vaccinia Immune Globulin

By Gender Type:

• Male
• Female
• Others

By Route of Administration:

• Oral
• Injection

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Monkeypox Vaccine and Treatment Market include Bavarian Nordic, Emergent BioSolutions, Johnson & Johnson, Moderna, Novavax, CanSino BioPharma, Gamaleya Research Institute, Bharat Biotech, Serum Institute of India, Takeda, Sanofi Pasteur, GSK, Merck, Pfizer, BioNTech.

              To Access More Companies, Request Free Sample Report

• In August 2022, The WHO declared monkeypox a PHEIC, which is definitely a game changer in the world's fight against the virus. The statement gave leverage to increased funding for international cooperation and actualized vaccine research. Following this declaration, most governments and health bodies launched more dynamic vaccination campaigns to combat this pandemic, especially in high-risk areas; the declaration also pushed pharmaceutical companies into fast-tracking R&D processes around vaccine candidates.
• In January 2023, the CDC revised its recommendations, extending the need for vaccination for monkeypox to include some high-risk groups. This step was based on the persistence of the spread of the virus on American soil and thus became a widely imperative call to protect vulnerable populations. The new guidelines contributed to more vaccine availability and distribution, particularly in areas hard hit by outbreaks. But this came with public health campaigns to urge vaccination amongst the newly eligible groups.

• Bavarian Nordic
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Emergent BioSolutions
• Johnson & Johnson
• Moderna
• Novavax
• CanSino BioPharma
• Gamaleya Research Institute
• Bharat Biotech
• Serum Institute of India
• Takeda
• Sanofi Pasteur
• GSK
• Merck
• Pfizer
• BioNTech

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Gender Type
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, By Product Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Vaccine
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
    • JYNNEOS/ Imvanex
    • Smallpox Vaccine
    • Others
• Drug
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
    • Tecovirimat
    • Brincidofovir
    • Cidofovir
    • Others
• Vaccinia Immune Globulin
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Gender Type, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Male
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Female
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Route of Administration, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Injection
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Distribution Channel, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Retail Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacies
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (USD Bn)

• Overview
  • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Gender Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Gender Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Gender Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Gender Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (USD Bn), By Product Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Gender Type, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (USD Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Bavarian Nordic
• Emergent BioSolutions
• Johnson & Johnson
• Moderna
• Novavax
• CanSino BioPharma
• Gamaleya Research Institute
• Bharat Biotech
• Serum Institute of India
• Takeda
• Sanofi Pasteur
• GSK
• Merck
• Pfizer
• BioNTech

The Last Word

• Future Impact
• About Us
• Contact